Market research
NLTX Neoleukin Therapeutics
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- 0.0%
- Beta
- 1.1
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US64049K1043
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- 0.0%
- Beta
- 1.1
About
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NLTX discussion.
5 years, 4 months ago
Neoleukin Therapeutics, Inc is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Neoleukin Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 310.8% to $-33M since the same quarter in the previous year.
Finally, its free cash flow fell by 82.4% to $-10M since the same quarter in the previous year.
Based on the above factors, Neoleukin Therapeutics, Inc gets an overall score of 1/5.